Canada Pension Plan Investment Board Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Canada Pension Plan Investment Board lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 24.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 454,407 shares of the company’s stock after purchasing an additional 89,235 shares during the period. Canada Pension Plan Investment Board owned 0.12% of Moderna worth $18,894,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc purchased a new position in shares of Moderna in the 4th quarter valued at approximately $37,000. Crowley Wealth Management Inc. bought a new stake in shares of Moderna during the fourth quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MRNA shares. Morgan Stanley reduced their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. Berenberg Bank raised their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Thursday. Finally, Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $58.70.

Moderna Stock Performance

Moderna stock opened at $24.72 on Monday. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The stock has a fifty day moving average of $30.84 and a 200 day moving average of $39.49. The stock has a market cap of $9.56 billion, a PE ratio of -2.66 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.